Show simple item record

dc.contributor.authorHannon, M J
dc.contributor.authorDinneen, S
dc.contributor.authorYousif, O
dc.contributor.authorThompson, C J
dc.contributor.authorQuigley, E M M
dc.contributor.authorO'Halloran, D J
dc.date.accessioned2011-07-25T11:55:58Z
dc.date.available2011-07-25T11:55:58Z
dc.date.issued2011-05
dc.identifier.citationGastric pacing for diabetic gastroparesis--does it work? 2011, 104 (5):135-7 Ir Med Jen
dc.identifier.issn0332-3102
dc.identifier.pmid21736087
dc.identifier.urihttp://hdl.handle.net/10147/136836
dc.description.abstractThe management of diabetic gastroparesis resistant to medical therapy is very difficult Gastric electrical stimulation (GES) is a relatively new therapeutic modality which has shown some promise in international trials. It has seen use in four patients in Ireland. Our aim was to determine if GES improved patients' outcomes in terms of duration and cost of inpatient stay and glycaemic control. We reviewed the patients' case notes and calculated the number of days spent as an inpatient with symptomatic gastroparesis pre and post pacemaker, the total cost of these admissions, and patients' average HbA1c pre and post GES. Mean length of stay in the year pre GES was 81.75 days and 62.25 days in the year post GES (p=0.89). There was also no improvement in glycaemic control following GES. GES has been ineffective in improving length of inpatient stay and glycaemic control in our small patient cohort.
dc.language.isoenen
dc.titleGastric pacing for diabetic gastroparesis--does it work?en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology and Metabolism, Cork University Hospital, Wilton, Cork. markjhannon2002@yahoo.co.uken
dc.identifier.journalIrish medical journalen
dc.description.provinceMunster
refterms.dateFOA2018-08-22T13:14:25Z
html.description.abstractThe management of diabetic gastroparesis resistant to medical therapy is very difficult Gastric electrical stimulation (GES) is a relatively new therapeutic modality which has shown some promise in international trials. It has seen use in four patients in Ireland. Our aim was to determine if GES improved patients' outcomes in terms of duration and cost of inpatient stay and glycaemic control. We reviewed the patients' case notes and calculated the number of days spent as an inpatient with symptomatic gastroparesis pre and post pacemaker, the total cost of these admissions, and patients' average HbA1c pre and post GES. Mean length of stay in the year pre GES was 81.75 days and 62.25 days in the year post GES (p=0.89). There was also no improvement in glycaemic control following GES. GES has been ineffective in improving length of inpatient stay and glycaemic control in our small patient cohort.


Files in this item

Thumbnail
Name:
21736087.pdf
Size:
12.68Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record